

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 186 672 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

13.03.2002 Bulletin 2002/11

(51) Int Cl.7: **C12Q 1/68, C07K 14/47,**
C07K 16/18

(21) Application number: **01306983.6**

(22) Date of filing: **17.08.2001**

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

- **Ambrose, Helen Jean**
Cheshire, SK10 4TG (GB)
- **Cresswell, Carl John**
Cheshire, SK10 4TG (GB)
- **Dudley, Adam Jeston**
Wilmington, DE 19850-5437 (US)

(30) Priority: **23.08.2000 US 226909 P**

(71) Applicant: **AstraZeneca AB**

151 85 Södertälje (SE)

- (74) Representative: **Giles, Allen Frank et al**
AstraZeneca PLC
Global Intellectual Property
Mereside
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(72) Inventors:

- **Adeokun, Monisola**
Cheshire, SK10 4TG (GB)

(54) **Polymorphisms in the human organic anion transporter C (OATP-C) gene**

(57) This invention relates to polymorphisms in the human OATPC gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic var-

iation in the OATPC gene, and to the use of OATPC polymorphism in treatment of diseases with OATPC transportable drugs such as statins.

EP 1 186 672 A2

Description

[0001] This invention relates to polymorphisms in the human OATPC gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATPC gene, and to the use of OATPC polymorphism in treatment of diseases with OATPC transportable drugs.

[0002] Na⁺-independent organic anion transporting polypeptide (OATP) C gene is a member of the OATP supergene family involved in multifunctional transport of organic anion. OATPC transports the organic anion taurocholate, conjugated steroids: DHEAS, estradiol 17 β -D-glucuronide and estrone-3-sulfate, eicosanoids: PGE₂, thromboxane B₂, leukotriene C₄, and E₄, and thyroid hormones T₄ and T₃^{1,2}. OATPC has also been shown to be involved in the transport of xenobiotics, and drugs involved in lipid lowering e.g. statins¹. Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases. The OATPC gene and its product is also thought to be of importance in other diseases due to its transport of DHEAS an adrenal steroid which has been suggested to have positive neuropsychiatric, immune, and metabolic effects³. Due to the substrate specificity, location in the liver, and being exclusively expressed in the liver, Abe *et al* suggested that OATPC could be the predominant clearance mechanism of several endogenous and exogenous substrates in the liver. OATPC is the first human molecule reported to transport thyroid hormones².

[0003] This liver specific transporter may be useful in liver-specific drug delivery systems and liver-specific chemotherapy, bile acid formation and the pathogenesis of diseases such as cholestasis, hyperbilirubinemia and thyroid hormone resistance.

[0004] The OATPC gene (sometimes called OAPT2 in the literature) has been cloned by four different groups, annotated and published as EMBL accession numbers AB026257 (OATPC, 2452bp), AF205071 (OATP2, 2830, ref 1), AJ132573 (OATP2, 2778)⁴, and AF060500 (LST-1)². Polymorphism has been reported by Tamai⁵ which is Asn130Asp and Val174Ala although any functional effect was stated therein to be not clear. König (2000) J Biol Chem 275, 23161-23168 describes the genomic organisation of OATP 1, 2 and 8. International patent application WO 00/08157 describes human anion transporter genes and some polymorphisms.

[0005] All positions herein of polymorphisms in the OATPC polynucleotide relate to the position in one of SEQ ID NO 1 or 3-12 unless stated otherwise or apparent from the context.

[0006] All positions herein of polymorphisms in the OATPC polypeptide relate to the position in SEQ ID NO 2 unless stated otherwise or apparent from the context.

[0007] One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

[0008] Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

[0009] Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

[0010] The present invention is based on the discovery of polymorphisms in OATPC.

[0011] According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATPC in a human, which method comprises determining the sequence of the human at at least one polymorphic position and determining the status of the human by reference to polymorphism in the OATPC gene. Preferred polymorphic positions are one or more of the following positions:

A method for the detection of a polymorphism in OATPC in a human, which method comprises determining the sequence of the human at at least one of the following polymorphic positions:

positions 510, 696, 1299, 1312, 1347, 1561, 2028, 2327 and 2342 in sequence of the OATPC gene as defined

¹ A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2), Hsiang *et al* J Biol Chem 274, 37161-37168 (1999)

² Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1, Takaaki Abe *et al* J Biol Chem 274, 17159-17163 (1999)

³ Bates *et al* (1998) Curr. Opin. Endocrinol. Diab. 5, 357-366

⁴ A novel human organic anion transporting polypeptide localised to the basolateral hepatocyte membrane, König Jorg *et al* (2000) Am J Physiol. Gastrointest. Liver Physiol. 278: G156-G164

⁵ Tamai *et al* (2000), BBRC, 273, 251-60

by the position in SEQ ID NO: 1;
 positions 400, 405, 488 and 643 in OATPC polypeptide defined by position in SEQ ID NO: 2;
 positions 321 and 1332 defined by position in SEQ ID NO 3;
 position 41 defined by position in SEQ ID NO 4;
 positions 109 and 244 defined by position in SEQ ID NO 5;
 positions 117 and 283 defined by position in SEQ ID NO 6;
 positions 209 and 211 defined by position in SEQ ID NO 7;
 positions 63 to 68 defined by position in SEQ ID NO 8;
 position 53 defined by position in SEQ ID NO 9;
 position 75 defined by position in SEQ ID NO 10;
 position 162 defined by position in SEQ ID NO 11; and
 positions 84 defined by position in SEQ ID NO 12.

[0012] The term human includes both a human having or suspected of having a OATPC mediated disease and an asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

[0013] The term polymorphism includes single nucleotide substitution, nucleotide insertion and nucleotide deletion which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene.

[0014] The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system and restriction fragment length polymorphism.

[0015] The status of the individual may be determined by reference to allelic variation at any one, two, three, four, five, six, seven, eight, nine or more positions.

[0016] The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

[0017] It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:	
ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer
HMG-CoA	3-hydroxy-3-methylglutaryl-coenzyme A
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay

(continued)

Abbreviations:	
NASBA	Nucleic acid sequence based amplification
OATP	Na ⁺ -independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

Table 1 -

Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation**Scanning:** PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage**Hybridisation Based**

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)**Extension Based:** ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.**Incorporation Based:** Mini-sequencing, APEX**Restriction Enzyme Based:** RFLP, Restriction site generating PCR**Ligation Based:** OLA**Other:** Invader assay

* Note: not useful for detection of promoter polymorphisms.

Table 2 -

Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)**Other:** Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 -

Further Amplification Methods
SSR, NASBA, LCR, SDA, b-DNA**[0018]** Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.**[0019]** Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™ is an especially preferred method.**[0020]** In a further aspect, the diagnostic methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATPC.

[0021] Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

[0022] Individuals who carry particular allelic variants of the OATPC gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

[0023] In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATPC. This may be particularly relevant in the development of hyperlipoproteinemia and cardiovascular disease and the present invention may be used to recognise individuals who are particularly at risk from developing these conditions.

[0024] In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATPC gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

[0025] In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

[0026] According to another aspect of the present invention there is provided a human OATPC gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

[0027] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0028] According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human OATPC gene and comprising an allelic variant selected from any one of the following:

Region	variant	Position in SEQ ID NO	SEQ ID NO
Exon 4	A	510	1
Exon 5	T	670	1
Exon 5	T	696	1
Exon 9	G	1299	1
Exon 9	A	1312	1
Exon 9	A	1347	1
Exon 10	C	1561	1
Exon 14	C	2028	1
3'UTR	Insert T	2327	1
3'UTR	C	2342	1
Promoter	G	321	3
Promoter	C	1332	3
Intron 1	A	41	4
Intron 2	G	109	5
Intron 2	G	244	5
Intron 3	A	117	6
Intron 3	A	283	6
Intron 4	A	209	7
Intron 4	A	211	7
Intron 4	Deletion CTTGTA	63	8
Intron 6	T	53	9

(continued)

Region	variant	Position in SEQ ID NO	SEQ ID NO
Intron 9	Insert TTC	75	10
Intron 11	Insert T	162	11
Intron 12	C	84	12

[0029] According to another aspect of the present invention there is provided a human OATPC gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

[0030] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0031] The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

[0032] According to another aspect of the present invention there is provided an allele specific primer capable of detecting a OATPC gene polymorphism, preferably at one or more of the positions as defined herein.

[0033] An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMSTM assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0034] An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

[0035] Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

[0036] According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a OATPC gene polymorphism, preferably at one or more of the positions defined herein.

[0037] The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0038] The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if, required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

[0039] According to another aspect of the present invention there is provided an allele specific primer or an allele specific oligonucleotide probe capable of detecting a OATPC gene polymorphism at one of the positions defined herein.

[0040] According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

[0041] The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

[0042] In another aspect of the invention, the single nucleotide polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of relatively high frequency. The OATPC gene is on chromosome 12p (as shown from a database search with the cDNA as a query sequence). Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as 2ⁿ haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation

at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

[0043] According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis.

[0044] According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATPC in which the method comprises:

i) detection of a polymorphism in OATPC in the human, which detection comprises determining the sequence of the human at one or more of the following positions:

positions 487, 510,, 554, 670, 696, 819, 820, 1299, 1312, 1347, 1561, 2028, 2327 and 2342 in sequence of the OATPC gene as defined by the position in SEQ ID NO: 1;
positions 130, 152, 174, 241, 400, 405, 488 and 643 in OATPC polypeptide defined by position in SEQ ID NO: 2;
positions 321 and 1332 defined by position in SEQ ID NO 3;
position 41 defined by position in SEQ ID NO 4;
positions 109 and 244 defined by position in SEQ ID NO 5;
positions 117 and 283 defined by position in SEQ ID NO 6;
positions 209 and 211 defined by position in SEQ ID NO 7;
positions 63 to 68 defined by position in SEQ ID NO 8;
position 53 defined by position in SEQ ID NO 9;
position 75 defined by position in SEQ ID NO 10;
position 162 defined by position in SEQ ID NO 11; and
positions 84 defined by position in SEQ ID NO 12.

and determining the status of the human by reference to polymorphism in the OATPC gene; and

ii) administering an effective amount of the drug.

[0045] Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in deciding on the effective amount of the statin drug or drugs. Statins already approved for use in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. The reader is referred to the following references for further information: *Drugs and Therapy Perspectives* (12th May 1997), 9: 1-6; Chong (1997) *Pharmacotherapy* 17: 1157-1177; Kellick (1997) *Formulary* 32: 352; Kathawala (1991) *Medicinal Research Reviews*, 11: 121-146; Jahng (1995) *Drugs of the Future* 20: 387-404, and *Current Opinion in Lipidology*, (1997), 8, 362 - 368. A preferred statin drug is compound 3a (S-4522) in Watanabe (1997) *Bioorganic and Medicinal Chemistry* 5: 437-444; now called rosuvastatin, see Olsson (2001) *American Journal of Cardiology*, 87, supplement 1, 33-36. The term "drug transportable by OATPC" means that transport by OATPC in humans is an important part of a drug exerting its pharmaceutical effect in man. For example, some statins have to be transported to the liver by OATPC to exert their lipid lowering effects.

[0046] According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATPC in which the method comprises:

i) diagnosis of a single nucleotide polymorphism in OATPC gene in the human, which diagnosis preferably comprises determining the sequence of the nucleic acid at position 487 in the coding sequence of the OATPC gene as defined by the position in SEQ ID NO: 1.

and determining the status of the human by reference to polymorphism in the OATPC gene; and

ii) administering an effective amount of the

[0047] Although the polymorphism at position 487 (A→G; Asn130Asp) was reported by Tamai, no functional effect was attributed. Indeed the following polymorphisms are known but have not previously been attributed a role in statin pharmacogenetics as disclosed herein.

OATPC polymorphisms
Position of nucleotide as in sequence 1 of OATPC patent

(continued)

OATPC polymorphisms					
Position of amino acid as in sequence 2 of OATPC patent					
Exon	nucleotide	SNP	Aminoacid	Change	Change
4	487	A>G	130	Asn>Asp	N>D
4	554	G>A	152	Arg>Lys	R>K
5	620	T>C	174	Val>Ala	V>A
5	670	C>T	191	Leu	L
6	819	A>T	240	Val	V
6	820	G>A	241	Asp>Asn	D>N

15 [0048] According to another aspect of the present invention there is provided use of a drug transportable by OATPC in preparation of a medicament for treating a disease in a human diagnosed as having a polymorphism therein, preferably at one or more of the positions defined herein. Preferably the disease is cardiovascular.

20 [0049] According to another aspect of the present invention there is provided a pharmaceutical pack comprising OATPC transportable drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism therein, preferably at one or more of the positions defined herein.

[0050] According to another aspect of the present invention there is provided an allelic variant of human OATPC polypeptide comprising at least one of the following:

- 25 a leucine at position 400 of SEQ ID NO 2;
- an isoleucine at position 405 of SEQ ID NO 2;
- an arginine at position 488 of SEQ ID NO 2;
- a phenylalanine at position 643 of SEQ ID NO 2;

30 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.

[0051] Fragments of polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids.

[0052] According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human OATPC polypeptide as described herein.

35 [0053] Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example F(ab')₂, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of OATPC with a K_a of greater than or equal to about 10⁷ M⁻¹. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660(1949).

40 [0054] Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to antigen. Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

50 [0055] Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

55 [0056] The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

[0057] Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

5 [0058] According to another aspect of the invention there is provided a diagnostic kit comprising an antibody of the invention.

[0059] The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

[0060] In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

[0061] AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

10 [0062] General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

[0063] Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2).

15 Example 1

Identification of Polymorphisms

1. Methods

20 DNA Preparation

[0064] DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Press, 1989) with the
25 following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

30 [0065] Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR. Where described below, the primary fragment was diluted 1/100 and two microlitres were used as template for amplification of secondary fragments. PCR was performed in two
35 stages (primary fragment then secondary fragment) to ensure specific amplification of the desired target sequence.

Polymorphisms in OATPC: cDNA screening of 15 Liver samples				
Region	SNP	Position	Amino Acid Change	Allele frequencies
40 Exon 4	G/A	510	None	G=96.7% A=3.3%
Exon 5	C/T	670	None	C=50% T=50%
45 Exon 5	C/T	696	None	C=60% T=40%
Exon 9	C/G	1299	Phe400Leu	C=96.7% G=3.3%
50 Exon 9	G/A	1312	Val405Ile	G=96.7% A=3.3%
Exon 9	G/A	1347	None	G=96.7% A=3.3%
55 Exon 10	G/C	1561	Gly488Arg	G=96.7% C=3.3%

EP 1 186 672 A2

(continued)

Polymorphisms in OATPC: cDNA screening of 15 Liver samples				
Region	SNP	Position	Amino Acid Change	Allele frequencies
Exon 14	A/C	2028	Leu643Phe	A=90% C=10%

[0066] OATP2 above refers to the clone sequenced by Hsiang et al (ref 1). Some comment on the numbering of exons in OATPC is required. This gene contains an exon (38 bp) upstream (5' UTR region) of the exon containing the ATG start site for translation. Therefore the exon numbering could vary depending whether this exon is counted as the first exon or not. In the literature, Konig (2000) JBC 275: 23161-68, have defined exon 1 as that containing the ATG start site and therefore we have adopted the same numbering in this application (but note that the priority document relating to the present application did vice versa; for example, exon 5 in this application is equivalent to exon 6 in the priority document).

PCR PRODUCTS		
Fragment	Forward Oligo	Reverse Oligo
443-999	443-466	979-999
874-1360	874-896	1337-1360
1255-1684	1255-1278	1663-1684
1559-2095	1559-1581	2073-2095

RFLP analysis			
Polymorphism	Position	RFLP Enzyme/PCR size	RFLP fragment size
G/A	510		
C/T	670	BmR I/595bp	C=349bp, 246bp T=595bp
C/T	696		
C/G	1299	Apo I/ 595bp	C=30bp, 60bp, 380bp G=90bp, 380bp
G/A	1312	Bst 4CI/ 595bp	G=77bp, 393bp A=470bp
G/A	1347		
G/C	1561	HpyCH4IV/595bp	G=470bp C=144bp, 326bp
A/C	2028	Ase I/ 577bp	A=89bp, 488bp C=577bp

Example 2

{0067}

5	Further OATPC Polymorphisms							
	SNPs in OATPC 3'UTR (positions according to SEQ ID NO 1)							
	Exon	Nucleotide	SNP				Frequency	Frequency
10							Caucasian	Japanese
	3' UTR	2327	Ins T				not screened	0.1
	3' UTR	2342	T>C				not screened	0.4
15								
	SNPs in OATPC promoter (positions according to SEQ ID NO 3)							
20		Nucleotide	SNP				Frequency	Frequency
							Caucasian	Japanese
		321	T>G				0.03	not screened
25		1332	A>C				0.08	not screened
30	SNPs in OATPC introns							
	Intron	Nucleotide	SNP	Nucleotide	Sequence			
		position in		position	ID No			
35		relation to exon		In sequence				
	1	IVS1+21	T>A	41	4			
	2	IVS2+89	T>G	109	5			
40	2	IVS2+224	A>G	244	5			
	3	IVS3+97	C>A	117	6			
	3	IVS3+263	G>A	283	6			
45	4	IVS4+189	G>A	209	7			
	4	IVS4+191	G>A	211	7			
	4	IVS5-118	delCTTGTA	63	8			
50	6	IVS6+33	C>T	53	9			
	9	IVS10-107	ins TTC	75	10			
	11	IVS11+142	Ins T	162	11			
55	12	IVS13-97	G>C	84	12			

OATPC Intronic SNPsKey

- 5 [0068] 20bp of exon sequence shown in uppercase
 Intron sequence in lowercase (200 to 300bp only)
 SNP shown in uppercase (one allele only)

10 Sequence ID No 4
 IVS1+21 T>A SNP at position 41 in this sequence

GATACTGCAA TGGATTGAAG gtagaataag ttttatgttt Ttgagctaaa ataagtaaat 60
 agggaaacttt aatgtataga aaagcaagtt gttaaaaaga acattatgtt tcaaattata 120
 15 attttcaatt gaagcatata ttgaaatatt aacataatga ttcatacctt gatttaaacc 180
 agtcttttaa tctgattaag 200

20 Sequence ID No 5
 IVS2+89 T>G SNP at position 109 in this sequence
 IVS2+224 A>G SNP at position 244 in this sequence

TGACGGAAGC TTGAAATTG gtaacattta ttttctattt taataaccaa acttgcaaag 60
 ttaaaaaata tatatgcttt acaccactgg ttatcaactg gggtaaatTt atctctcaca 120
 25 ggcaatttgg caataactaa aaacatttgt ggtgtcata actgcacagg ggttgggggc 180
 aatggaagtg ctactggtat ctaaaggtag aggtcagggg tactgctaaa tattctataa 240
 tgcAcaaaga atgatgtaac tgaaaatgtt gatagtgagg atgttcagaa accctgattc 300

30 Sequence ID No 6
 IVS3+97 C>A SNP at position 117 in this sequence
 IVS3+263 G>A SNP at position 283 in this sequence

35

CCACATTTCT TCATGGGATA gtaagtgtta aaaaaaaaaa aaacctctgt gccactatca 60
 gtaccttgta aattaggagt agaattttat tattatccct ttaaataaggc agttacCttt 120
 40 tgagaagata cccactaagt gtgtacagaa atgaaatagt gtctatttgt ctacataatc 180
 attttattta tcgtagcttt catatacttt gaaataacaa aaagactaaa ctgtagagtt 240
 tcaaatgaaa taaataggct ttttatgaat ttttagtata acGtatatac tgtacgtctt 300

45 Sequence ID No 7
 IVS4+189 G>A SNP at position 209 in this sequence
 IVS4+191 G>A SNP at position 211 in this sequence

ACCTGAGATA GTGGGAAAAG gtaagaatta atattgacag taaaaagtct tctaaaaatgt 60
 50 atacatttaa ttacatctct aaaaattggt gtgatattca ttagcaaaat ttaattaaga 120
 atgaatagga aaaacatttg actcttacag acataattat agtgtaata tacacagttc 180
 gccatttaac aacacagggt taaactacGc Gttttcactt ctatgcaaat tttgtccatc 240
 tgaactggat gataaacctg ccggtgaaga tatctgacat tttctatatt tggattgaac 300

55

Sequence ID No 8

IVS5-118 delCTTGTA deletion of 6bp from position 63 to 68 incl.

5 tagcagcata agaattggact aatacaccat attgtcaaag ttgcaaagt gaataataat 60
 taCTTGTAAct tgtaaattaa aaaaaataa gtagaataat taagagtta caagtagtta 120
 aatttgtaat agaaatgcta aaattaatgt ttaaaatgaa acactctctt atctacatag 180
 GTTGTTTAAA GGAATCTGGG 200

10

Sequence ID No 9IVS6+33 C>T SNP at position 53 in this sequence

TATTGGATAT GTAGATCTAA gtaagtacaa ccagaacaag gtacatgat aaCgtctttc 60
 taagcacaca tgcgaaaaac attttttcaa ataactgaat tcaactcttc aatagtcctt 120
 tgcttaatat aattagaaag ttacaagtag gaaataaatg tattactaat cagaataaat 180
 ataaaatcca gtcctctattt 200

15

Sequence ID No 10

IVS10-107 Ins TTC SNP at position 75 in this sequence

20 ttaaaaaaaa ctttgccatt tgcgtcatcat caaagcaaat ttcttcatat aaagaaaaat 60
 tctttatcta cttt(TTC)ttttcc ctctttctct gctttcactt tacttcttcc ttctctccc 120
 cttctttgtc tttttcttct ctctctctct ttttgatata tgcctatcat atatttccag 180
 AAATAATCCA GTGACATCTC 200

25

Sequence ID No 11

IVS11+142 InsT InsT at position 162 in this sequence

30 CATGTCATGC TGATTGTTAA gtaagtatga cttttaaaaa cattttcata tgcattgagac 60
 tataaacaca cctaattgata tgcatttttt tacataatat actgggaatt caaattcata 120
 ttcatcaaaa tttaatttt ctgagaattc attttattaa aa(T)ttactatg aactctcaag 180
 gctgtaatta ataattttgc 200

35

Sequence ID No 12

IVS13-97 G>C SNP at position 84 in this sequence

40 tgatttgggt ctttgagatt tctaataatc tttattattg ggtagatgca gaacaaaaata 60
 ataaacgaat cctccaaatt ttGaaacttt tatttaataa aaatatatca atgtggaata 120
 tcatgcagtt acatttaaaa tatgttcctt aaactgacat cttctcttct cctattacag 180
 GAGGAATTCT AGCTCCAATA 200

OATPC promoter region

45 [0069] Total length of the sequence = 1538bp
 1500bp of OATPC sequence directly upstream from the cDNA sequence
 Sequence in uppercase represents 38bp overlap with the cDNA sequence (SEQ ID NO 1) where this 38bp is 5'UTR
 sequence.
 Nucleotide positions in the promoter have been determined where the -1 position is the base (lowercase) directly
 50 upstream of the end of the cDNA sequence.

55

EP 1 186 672 A2

atgctctttg acctctgaaa atattggaga attttacaac tggcaccttt agctcaggat 60
 tataaagggt gttagttagt ttgtactggt ttatcttcat tgtatataat atatatatta 120
 gctctcaaac atggtgatgt gttttcaatg aaatggatgt ctgaggagaa aaccatttagc 180
 ctgagaaaaac ccaaactgta ttcccatgtt gaataaaaagg aagtccataa aaatgatgga 240
 5 aaatgttctg cattcctggt atgatatcaa aatctggcag tacatgaaaa tttttcaaag 300
 tgcttattta acaggcataa tctttgggtc cctgagccag aatctgctgg gtatgggact 360
 ggattgctat ttgacaact cgccagtaga ttcttactca gcagagtatt tggaaacctt 420
 actctaatat ttggccttg ggtctacatt tctcagttct gcacagtcac tcttcccttc 480
 tacactactc tttagtttgt ctcatgattc caatactctc aataattaac caagaataga 540
 actaatcaat cagataactg tggcacagac atcaaataca ttttgctgca accatatcaa 600
 10 caaatgtccc atgaatgata aggggtaacc atattctcat atatgcatcc tcacattacc 660
 acatatatat atgtgcatat gtgtatacag gtaaaagtgt gtatatatgt atacatgtat 720
 gtttgtgtgt atatacatat atatatcttc acacttttct gaaatatata tttttatgtg 780
 agagaagggt ctgtacttta ttccagaaga gagcttaatg tccaagggtat aattgagagt 840
 ctaaaatggt tgagttattg aattaattaa acttcatctc tactcaagaa aacttttaac 900
 tgagttaaagc tcttcctttc tccacaagtc aagtcaataa aaggaaactg tgatattaat 960
 15 aattctttcc tgttttgatg taaagaatct atcgcataaa gcagtccttaa ttttcatcat 1020
 tcagaaaaat ggtcttgtag ttaattggga ctctcttatt ccaggtggta tctccagtct 1080
 ccatacatat cactttagaa ccatacttat gtaccaagca aagagggtat attttaattt 1140
 ttaaatgcca atgtaacctg taggcatatt ttttatttgt cttaaatat ttcctatttg 1200
 gaagttttaa atacctggaa taatttattg tactcatatt tttaaagaaa aaaatcttat 1260
 gccaccaact taattgaata aacaagtata agccattccc aaaagtaagg tttacttggt 1320
 20 aagattaaca aaaaaataatg tgagaattct gagaaatata atctttaaat a:tggaact 1380
 ggagtgaact cttaaaacta actaggtttt atatgtttga ctagagcaat gacataataa 1440
 ggtggttaat catcactgga cttgttttca aaaagccaac tactttaaga ggaataaagg 1500
 GTGGACTTGT TGCAGTTGCT GTAGGATTCT AAATCCAG 1538

25
 30
 35
 40
 45
 50
 55

SEQUENCE LISTING

<110> AstraZeneca AB

<120> Chemical Compounds

<130> adeokun
ambrose
cresswell
dudley

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 2452

<212> DNA

<213> Homo sapiens

<400> 1

```

gtggacttgt tgcagttgct gtaggattct aaatccaggt gattgtttca aactgagcat 60
caacaacaaa aacatttcta tgatatctat atttcaatca tggacaaaaa tcaacatttg 120
aataaaaacag cagaggcaca accttcagag aataagaaaa caagatactg caatggattg 180
aagatgttct tggcagctct gtcactcagc ttatttgcta agacactagg tgcaattatt 240
atgaaaagtt ccatcattca tatagaacgg agatttgaga tatectcttc tctgttgggt 300
tttattgacg gaagctttga aattggaaat ttgcttgta ttgtatttgt gagttacttt 360
ggatccaaac tacatagacc aaagttaatt ggaatcggtt gttcattat ggaattgga 420
ggtgttttga ctgctttgcc acattttctt atgggatatt acagggtattc taaagaaact 480
aatatcaatt catcagaaaa ttcaacatcg accttatcca cttgtttaat taatcaaat 540
ttatcactca atagagcacc acctgagata gtgggaaaaa gttgtttaaa ggaatctggg 600
tcatacatgt ggatatatgt gttcatgggt aatatgcttc gtggaatagg ggagactccc 660
atagtaccac tggggctttc ttacattgat gatttcgcta aagaaggaca ttctctcttg 720
tattttagga tattgaatgc aatagcaatg attggtccaa tcattggctt taccctggga 780
tctctgtttt ctaaaatgta cgtggatatt ggatatgtag atctaagcac tatcaggata 840
actcctactg attctcgatg ggttggagct tggctgctta atttccttgt gtcctgga 900
ttctccatta tttcttccat accattcttt ttcttgcccc aaactccaaa taaaccacaa 960
aaagaaaagaa aagcttcact gtctttgcat gtgctggaaa caaatgatga aaaggatcaa 1020
acagctaatt tgaccaatca aggaaaaaat attacaaaa atgtgactgg tttttccag 1080
tcttttaaaa gcacccctac taatccccctg tatgttatgt ttgtgctttt gacgttggtta 1140
caagtaagca gctatatggg tgcttttact tatgtcttca aatacgtaga gcaacagtat 1200
ggtcagcctt catctaaggc taacatctta ttgggagtc taaccatacc tatttttgca 1260
agtggaaatg ttttaggagg atatatcatt aaaaaattca aactgaacac cgttggaaat 1320
gccaaaattct catgttttac tgctgtgatg tcattgtcct ttacctatt atattttttc 1380
atactctgtg aaaacaaatc agttgccgga ctaaccatga cctatgatgg aaataatcca 1440
gtgacatctc atagagatgt accactttct tattgcaact cagactgcaa ttgtgatgaa 1500
agtcaatggg aaccagctcg tggaaacaat ggaataactt acatctcacc ctgtctagca 1560
ggttgcaaat cttcaagtgg caataaaaaa cctatagtgt tttaactg cagttgtttg 1620
gaagtaactg gtctccagaa cagaaattac tcagcccat tgggtgaaat cccaagagat 1680
gatgcttgta caaggaaatt ttactttttt gttgcaatac aagctctgaa ttattttttc 1740
tctgcacttg gaggcacctc acatgtcatg ctgattgtta aaattgttca acctgaattg 1800
aatcactttg cactgggttt ccaactcaatg gttatacgag cactaggagg aattctagct 1860
ccaatatatt ttggggctct gattgatata acgtgtataa agtgggtccac caacaactgt 1920
ggcacacgtg ggtcatgtag gacatataat tcacatcat ttccaagggt ctacttgggc 1980
ttgtcttcaa tgttaagagt ctcactcatt gttttatata ttatattaa: ttatgccatg 2040
aagaaaaaat atcaagagaa agatatcaat gcatcagaaa atggaagtgt catggatgaa 2100
gcaaaacttag aatccttaaa taaaaataaa cattttgtcc ctctctgtgg ggcagatagt 2160
gaaacacatt gtttaaggga gaaaaaaagc cacttctgct tctgtgtttc caaacagcat 2220
tgattgatt cagtaagatg ttatttttga ggagtctctg gtcccttcac taagaatttc 2280
cacatctttt atggtggaag tataaataag cctatgaact tataataaaa caaactgtag 2340
gtagaaaaaa tgagagtact cattgtacat tatagctaca tatttgtgg: taaggttaga 2400
ctatatgatc catacaaatt aaagtggag acatggttac tgtgtaataa aa 2452

```

EP 1 186 672 A2

<210> 2
 <211> 691
 <212> PRT
 <213> Homo sapiens

5 <400> 2
 Met Asp Gln Asn Gln His Leu Asn Lys Thr Ala Glu Ala Gln Pro Ser
 1 5 10 15

10 Glu Asn Lys Lys Thr Arg Tyr Cys Asn Gly Leu Lys Met Phe Leu Ala
 20 25 30

Ala Leu Ser Leu Ser Phe Ile Ala Lys Thr Leu Gly Ala Ile Ile Met
 35 40 45

15 Lys Ser Ser Ile Ile His Ile Glu Arg Arg Phe Glu Ile Ser Ser Ser
 50 55 60

Leu Val Gly Phe Ile Asp Gly Ser Phe Glu Ile Gly Asn Leu Leu Val
 65 70 75 80

10 Ile Val Phe Val Ser Tyr Phe Gly Ser Lys Leu His Arg Pro Lys Leu
 85 90 95

20 Ile Gly Ile Gly Cys Phe Ile Met Gly Ile Gly Gly Val Leu Thr Ala
 100 105 110

Leu Pro His Phe Phe Met Gly Tyr Tyr Arg Tyr Ser Lys Glu Thr Asn
 115 120 125

25 Ile Asn Ser Ser Glu Asn Ser Thr Ser Thr Leu Ser Thr Cys Leu Ile
 130 135 140

Asn Gln Ile Leu Ser Leu Asn Arg Ala Ser Pro Glu Ile Val Gly Lys
 145 150 155 160

30 Gly Cys Leu Lys Glu Ser Gly Ser Tyr Met Trp Ile Tyr Val Phe Met
 165 170 175

Gly Asn Met Leu Arg Gly Ile Gly Glu Thr Pro Ile Val Pro Leu Gly
 180 185 190

35 Leu Ser Tyr Ile Asp Asp Phe Ala Lys Glu Gly His Ser Ser Leu Tyr
 195 200 205

Leu Gly Ile Leu Asn Ala Ile Ala Met Ile Gly Pro Ile Ile Gly Phe
 210 215 220

40 Thr Leu Gly Ser Leu Phe Ser Lys Met Tyr Val Asp Ile Gly Tyr Val
 225 230 235 240

Asp Leu Ser Thr Ile Arg Ile Thr Pro Thr Asp Ser Arg Trp Val Gly
 245 250 255

45 Ala Trp Trp Leu Asn Phe Leu Val Ser Gly Leu Phe Ser Ile Ile Ser
 260 265 270

Ser Ile Pro Phe Phe Phe Leu Pro Gln Thr Pro Asn Lys Pro Gln Lys
 275 280 285

50 Glu Arg Lys Ala Ser Leu Ser Leu His Val Leu Glu Thr Asn Asp Glu
 290 295 300

Lys Asp Gln Thr Ala Asn Leu Thr Asn Gln Gly Lys Asn Ile Thr Lys
 305 310 315 320

55 Asn Val Thr Gly Phe Phe Gln Ser Phe Lys Ser Ile Leu Thr Asn Pro
 325 330 335

EP 1 186 672 A2

Leu Tyr Val Met Phe Val Leu Leu Thr Leu Leu Gln Val Ser Ser Tyr
 340 345 350
 5 Ile Gly Ala Phe Thr Tyr Val Phe Lys Tyr Val Glu Gln Gln Tyr Gly
 355 360 365
 Gln Pro Ser Ser Lys Ala Asn Ile Leu Leu Gly Val Ile Thr Ile Pro
 370 375 380
 10 Ile Phe Ala Ser Gly Met Phe Leu Gly Gly Tyr Ile Ile Lys Lys Phe
 385 390 395 400
 Lys Leu Asn Thr Val Gly Ile Ala Lys Phe Ser Cys Phe Thr Ala Val
 405 410 415
 15 Met Ser Leu Ser Phe Tyr Leu Leu Tyr Phe Phe Ile Leu Cys Glu Asn
 420 425 430
 Lys Ser Val Ala Gly Leu Thr Met Thr Tyr Asp Gly Asn Asn Pro Val
 435 440 445
 20 Thr Ser His Arg Asp Val Pro Leu Ser Tyr Cys Asn Ser Asp Cys Asn
 450 455 460
 Cys Asp Glu Ser Gln Trp Glu Pro Val Cys Gly Asn Asn Gly Ile Thr
 465 470 475 480
 25 Tyr Ile Ser Pro Cys Leu Ala Gly Cys Lys Ser Ser Ser Gly Asn Lys
 485 490 495
 Lys Pro Ile Val Phe Tyr Asn Cys Ser Cys Leu Glu Val Thr Gly Leu
 500 505 510
 30 Gln Asn Arg Asn Tyr Ser Ala His Leu Gly Glu Cys Pro Arg Asp Asp
 515 520 525
 Ala Cys Thr Arg Lys Phe Tyr Phe Phe Val Ala Ile Gln Val Leu Asn
 530 535 540
 35 Leu Phe Phe Ser Ala Leu Gly Gly Thr Ser His Val Met Leu Ile Val
 545 550 555 560
 Lys Ile Val Gln Pro Glu Leu Lys Ser Leu Ala Leu Gly Phe His Ser
 565 570 575
 40 Met Val Ile Arg Ala Leu Gly Gly Ile Leu Ala Pro Ile Tyr Phe Gly
 580 585 590
 Ala Leu Ile Asp Thr Thr Cys Ile Lys Trp Ser Thr Asn Asn Cys Gly
 595 600 605
 Thr Arg Gly Ser Cys Arg Thr Tyr Asn Ser Thr Ser Phe Ser Arg Val
 610 615 620
 45 Tyr Leu Gly Leu Ser Ser Met Leu Arg Val Ser Ser Leu Val Leu Tyr
 625 630 635 640
 Ile Ile Leu Ile Tyr Ala Met Lys Lys Lys Tyr Gln Glu Lys Asp Ile
 645 650 655
 50 Asn Ala Ser Glu Asn Gly Ser Val Met Asp Glu Ala Asn Leu Glu Ser
 660 665 670
 Leu Asn Lys Asn Lys His Phe Val Pro Ser Ala Gly Ala Asp Ser Glu
 675 680 685
 55 Thr His Cys

690

5 <210> 3
 <211> 1538
 <212> DNA
 <213> Homo sapiens

10 <400> 3
 atgctctttg acctctgaaa atattggaga attttacaac tggcaccctt agctcaggat 60
 tataaagggt gttagttagt ttgtactgtt ttatcttcat tgtatataat atatatatta 120
 gtctccaaac atgttgatgt gttttcaatg aaatggatgt ctgaggagaa aaccattagc 180
 ctgagaaaaa ccaaaactga tccccattgt gaataaaagg aagtcataaa aaatgatgga 240
 aaatgttctg cattctctgt atgatatcaa aatctggcag tacatcaaaa tttttcaaaag 300
 tgcttattta acaggcataa tctttggtct cctgagccag aatctgctgg gtatgggact 360
 ggattgctat ttgacaact cggcagtaga ttcttactca gcagagtatt tgggaagcctt 420
 15 actctaataa tttggccttg ggtctacatt tctcagttct gcacagtcatt tcttccccctc 480
 tacactactc tttagtttgt ctcatgattc caatactc c aataattaac caagaataga 540
 actaatcaat cagataactg tggcacagac atcaaataca ttttgctgca accatatcaa 600
 caaatgtccc atgaatgata aggggtaacc atattctcat atatgcatcc tcacattacc 660
 acatatatat atgtgcataa ggtatataca gtaaaaagtgt gtatatatgt atacatgtat 720
 gtttgtgtgt atatacatat atatatcttc acacttttct gaaatatata tttttatgtg 780
 20 agagaagggt ctgtacttta tttcagaaga gagcttaagt tccaagctat aattgagagt 840
 ctaaaatggt tgagttattg aattaattaa acttcatctc tactcaagaa aacttttaac 900
 tgagttaagc tcttcttttc tccacaagtc aagtcataaa aaggaaactg tgatatattat 960
 aattcttttc tgttttgatg taaagaatct atgcataaaa gcagtcctaa ttttcatcat 1020
 tcagaaaaat ggtcttgtag ttaattggga ctctcttatt ccaggtggtg tctccagctc 1080
 ccatacatat cactgttaga ccatacttat gtaccaagca aagagggtat attttaattt 1140
 25 ttaaatgccat atgtaacctg taggcattat ttttatttgt cttaaaattat ttcctatttg 1200
 gaagttttaa atacctggaa taattttatt tactcatatt tttaaagaaa aaaatcttat 1260
 gccaccaact taattgaata aacaagtaaa agccattccc aaaagtaagg tttacttgtt 1320
 aagattaaca aaaaaataat tgagaattct gagaaatata atctttaaat attggcaact 1380
 ggagtgaact cttaaaacta actagggttt atatgtttga ctagaaccaat gacataataa 1440
 30 ggtggttaat catcactgga cttgttttca aaaagccaac tactttaaga ggaataaaagg 1500
 gtggacttgt tgcagttgct gtaggattct aaatccag 1538

35 <210> 4
 <211> 200
 <212> DNA
 <213> Homo sapiens

40 <400> 4
 gatactgcaa tggattgaag gtagaataag ttttatgttt ttgagctaaa ataagtaaat 60
 agggaaacttt aatgtataga aaagcaagtt gttaaaaaga acattatgtt tcaaatata 120
 attttcaatt gaagcatata ttgaaatatt aacataatga ttcatacttt gatttaaac 180
 agtcttttaa tctgattaa 200

45 <210> 5
 <211> 300
 <212> DNA
 <213> Homo sapiens

50 <400> 5
 tgacgggaagc tttgaaattg gtaacattta ttttctattt taataaccaa acttgcaaaag 60
 ttaaaaaata tatatgcttt acaccactgg ttatcaactg gggtaaatat atctctcaca 120
 ggcaatttgg caataactaa aaacatttgt ggttgcata actgcacagg ggttgggggc 180
 aatggaagtg ctactggtat cttaaaggtag aggtcagggg tactgctaaa tattctataa 240
 55 tgcacaaaga atgatgtaac tgaataatgt gatagtgaag atgttcagaa accctgattc 300

55 <210> 6
 <211> 300
 <212> DNA
 <213> Homo sapiens

<400> 6

EP 1 186 672 A2

5 ccacatttct tcargggata gtaagtgtta aaaaaaaaaa aaacctctgt gccactatca 60
gtaccttgta aattaggagt agaattttat tattatccct ttaaataggc agttaccttt 120
tgagaagata cccactaagt gtgtacagaa atgaaatagt gtctatttgt ctacataatc 180
attttattta tcgtagcttt catatacttt gaaataacaa aaagactaaa ctgtagagtt 240
tcaaatgaaa taaataggct ttttatgaat ttttagtata acgtatatac tgtacgtctt 300

10 <210> 7
<211> 300
<212> DNA
<213> Homo sapiens

15 <400> 7
acctgagata gtgggaaaag gtaagaatta atattgacag taaaaagtct tctaaaaagt 60
atacatttaa ttacatctct aaaaattggt gtgatattca ttagcaaaat ttaartaaga 120
atgaatagga aaaacatttg actcttacag acataattat agtgttaata tacacagttc 180
gcccattaac aacacaggtt taaactacgc gttttcactt ctatgcaaat ttgtccatc 240
tgaactggat gataaacctg ccggaagaa tatctgacat tttctatatt tggattgaac 300

20 <210> 8
<211> 200
<212> DNA
<213> Homo sapiens

25 <400> 8
tagcagcata agaattggact aatacaccat attgtcaaag ttgcaaaagt gaataataat 60
tactttgact tgtaaattaa aaaaaataa gtagaataat taagagttaa caagcagtta 120
aatttgtaat agaaatgcta aaattaatgt ttaaaatgaa acactctctt atctacatag 180
gttggtttaa ggaatctggg 200

30 <210> 9
<211> 200
<212> DNA
<213> Homo sapiens

35 <400> 9
tattggatat gtagatctaa gtaagtacaa ccagaacaag gtaccatgat aacgtctttc 60
taagcacaca tgcgaaaaac attttttcaa ataactgaat tcactctttc aatagtcctt 120
tgcttaatat aattagaaag ttacaagtag gaaataaatg tattactaat cagaataaat 180
ataaaatcca gctcctattt 200

40 <210> 10
<211> 203
<212> DNA
<213> Homo sapiens

45 <400> 10
ttaaaaaaa ctttgccatt tcgtcatcat caaagcaaatt tttttcatat aaagaaaaat 60
tctttatcta ctttttcttt tccctctttc tctgctttca ctttactttt tctttctctt 120
ccccttcttt gtctttttct tctctctctc tctttttgat atagctctat catatatttc 180
cagaaataat ccagtgcacat ctc 203

50 <210> 11
<211> 201
<212> DNA
<213> Homo sapiens

55 <400> 11
catgtcatgc tgattgttaa gtaagtatga cttttaaaaa cattttcata tgcattgagac 60
tataaacaca cctaagtata tgcataattt tacataatat actgggaatt caaattcata 120
tttcatcaaa ttttaatttt ctgagaattc attttatata aatttactat gaactctcaa 180
ggctgtaatt aataattttg c 201

EP 1 186 672 A2

<210> 12
 <211> 200
 <212> DNA
 <213> Homo sapiens

 <400> 12
 tgatttgggt ctttgagatt tctaataatc tttattattg ggtagatgca gaacaaaata 60
 ataaacgaat cctccaaatt tttgaacttt tatttaatca aaatatatca atgtggaata 120
 tcatgcagtt acatttaaaa tatgttcctt aaactgacat cttctcttct cctattacag 180
 gaggaattct agctccaata 200

Claims

1. A method for the detection of a polymorphism in OATPC in a human, which method comprises determining the sequence of the human at at least one of the following polymorphic positions:

positions 510, 696, 1299, 1312, 1347, 1561, 2028, 2327 and 2342 in sequence of the OATPC gene as defined by the position in SEQ ID NO: 1;
 positions 400, 405, 488 and 643 in OATPC polypeptide defined by position in SEQ ID NO: 2;
 positions 321 and 1332 defined by position in SEQ ID NO 3;
 position 41 defined by position in SEQ ID NO 4;
 positions 109 and 244 defined by position in SEQ ID NO 5;
 positions 117 and 283 defined by position in SEQ ID NO 6;
 positions 209 and 211 defined by position in SEQ ID NO 7;
 positions 63 to 68 defined by position in SEQ ID NO 8;
 position 53 defined by position in SEQ ID NO 9;
 position 75 defined by position in SEQ ID NO 10;
 position 162 defined by position in SEQ ID NO 11; and
 positions 84 defined by position in SEQ ID NO 12.

2. Use of a method as defined in claim 1 to assess the pharmaco genetics of a drug transportable by OATPC.

3. A polynucleotide comprising at least 20 bases of the human OATPC gene and comprising an allelic variant selected from any one of the following:

Region	variant	Position in SEQ ID NO	SEQ ID NO
Exon 4	A	510	1
Exon 5	T	670	1
Exon 5	T	696	1
Exon 9	G	1299	1
Exon 9	A	1312	1
Exon 9	A	1347	1
Exon 10	C	1561	1
Exon 14	C	2028	1
3'UTR	Insert T	2327	1
3'UTR	C	2342	1
Promoter	G	321	3
Promoter	C	1332	3
Intron 1	A	41	4

(continued)

Region	variant	Position in SEQ ID NO	SEQ ID NO
Intron 2	G	109	5
Intron 2	G	244	5
Intron 3	A	117	6
Intron 3	A	283	6
Intron 4	A	209	7
Intron 4	A	211	7
Intron 4	Deletion CTTGTA	63	8
Intron 6	T	53	9
Intron 9	Insert TTC	75	10
Intron 11	Insert T	162	11
Intron 12	C	84	12

4. A nucleotide primer which can detect a polymorphism as defined in claim 1.
5. An allele specific primer capable of detecting a OATPC gene polymorphism as defined in claim 1.
6. An allele-specific oligonucleotide probe capable of detecting a OATPC gene polymorphism as defined in claim 1.
7. Use of an OATPC polymorphism as defined in claim 1 as a genetic marker in a linkage study.
8. Use of a drug transportable by OATPC in preparation of a medicament for treating a disease in a human detected as having a OATPC polymorphism at one or more of the following positions:

positions 487, 510,, 554, 670, 696, 819, 820, 1299, 1312, 1347, 1561, 2028, 2327 and 2342 in sequence of the OATPC gene as defined by the position in SEQ ID NO: 1;
 positions 130, 152, 174, 241, 400, 405, 488 and 643 in OATPC polypeptide defined by position in SEQ ID NO: 2;
 positions 321 and 1332 defined by position in SEQ ID NO 3;
 position 41 defined by position in SEQ ID NO 4;
 positions 109 and 244 defined by position in SEQ ID NO 5;
 positions 117 and 283 defined by position in SEQ ID NO 6;
 positions 209 and 211 defined by position in SEQ ID NO 7;
 positions 63 to 68 defined by position in SEQ ID NO 8;
 position 53 defined by position in SEQ ID NO 9;
 position 75 defined by position in SEQ ID NO 10;
 position 162 defined by position in SEQ ID NO 11; and
 positions 84 defined by position in SEQ ID NO 12.

9. A use according to claim 10 in which the drug is a statin.
10. A use according to claim 10 in which the drug is rosuvastatin.
11. An allelic variant of human OATPC polypeptide comprising at least one of the following:
 - a leucine at position 400 of SEQ ID NO 2;
 - an isoleucine at position 405 of SEQ ID NO 2;
 - an arginine at position 488 of SEQ ID NO 2;
 - a phenylalanine at position 643 of SEQ ID NO 2;

or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic

variant.

12. An antibody specific for an allelic variant of human OATPC polypeptide as defined in claim 11.

5

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 186 672 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
25.09.2002 Bulletin 2002/39

(51) Int Cl.7: **C12Q 1/68**, **C07K 14/47**,
C07K 16/18

(43) Date of publication A2:
13.03.2002 Bulletin 2002/11

(21) Application number: **01306983.6**

(22) Date of filing: **17.08.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

- **Ambrose, Helen Jean**
Cheshire, SK10 4TG (GB)
- **Cresswell, Carl John**
Cheshire, SK10 4TG (GB)
- **Dudley, Adam Jeston**
Wilmington, DE 19850-5437 (US)

(30) Priority: **23.08.2000 US 226909 P**

(71) Applicant: **AstraZeneca AB**
151 85 Södertälje (SE)

(74) Representative: **Giles, Allen Frank et al**
AstraZeneca PLC
Global Intellectual Property
Mereside
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(72) Inventors:
• **Adekun, Monisola**
Cheshire, SK10 4TG (GB)

(54) **Polymorphisms in the human organic anion transporter C (OATP-C) gene**

(57) This invention relates to polymorphisms in the human OATPC gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic var-

iation in the OATPC gene, and to the use of OATPC polymorphism in treatment of diseases with OATPC transportable drugs such as statins.

EP 1 186 672 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 01 30 6983 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	WO 00 08157 A (HU PING ;LAUBERT BORIS (US); AXYS PHARM INC (US); BUCKLER ALAN J) 17 February 2000 (2000-02-17) * page 6, line 18 - page 8, line 27 * * page 11, line 18 - page 16, line 32 * * example 1 * * claims 1-5,10,15,17 *	1-3,5-7	C12Q1/68 C07K14/47 C07K16/18
A	---	11,12	
	-/--		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search :</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		15 July 2002	Ulbrecht, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons 6 : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 02 02 (P4-C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 01 30 6983

Claim(s) searched incompletely:
5

Claim(s) not searched:
4

Reason for the limitation of the search:

1) As essentially any primer hybridising to the chromosome harbouring the OATPC gene is suitable for the detection of the claimed OATPC polymorphisms and as furthermore the length of said primer is subject to almost infinite variation, the subject-matter of claim 4 lacks clarity within the meaning of Article 84 to an extent as to render a meaningful search of said claim impossible.

2) The term allele specific primer used in claim 5 is not clear causing problems in construing the scope of said claim (Article 84 EPC). Based on the description of the present application the search for such a primer was limited to a primer applicable to ARMS methodology in which the polymorphic position is located at the 3' end of said primer.

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 6983

DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X,D	TAMAI I ET AL.: "MOLECULAR IDENTIFICATION AND CHARACTERIZATION OF NOVEL MEMBERS OF THE HUMAN ORGANIC ANION TRANSPORTER (OATP) FAMILY" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 273, no. 1, 2000, pages 251-260, XP000941538 ISSN: 0006-3002 * page 252, left-hand column, paragraph 4 - right-hand column, paragraph 3 * * page 253, right-hand column, paragraph 2 - page 254, right-hand column, line 1 * * figures 1,3,4 *	1-3,5-7
A	& DATABASE EMBL [Online] EBI; 8 June 1999 (1999-06-08) TAMAI I ET AL.: "Homo sapiens mRNA for organic anion transporter OATP-C" retrieved from HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH Database accession no. AB026257 * the whole document *	11,12 1-3,5-7, 11,12
A	DATABASE EMBL [Online] EBI; 2 February 2000 (2000-02-02) MUZNY DM ET AL.: "Homo sapiens 12p BAC RP11-12505" retrieved from HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH Database accession no. AC022335 XP002188259 * the whole document *	1-3,5-7



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 30 6983

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A,D	<p>HSIANG B ET AL: "A NOVEL HUMAN HEPATIC ORGANIC ANION TRANSPORTING POLYPEPTIDE (OATP2)"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US,</p> <p>vol. 274, no. 52, 1999, pages 37161-37168, XP000877290</p> <p>ISSN: 0021-9258</p> <p>* abstract *</p> <p>* page 37164, right-hand column, paragraph 2 *</p> <p>* figures 3,4 *</p>	1-3,5-7, 11,12	
A	<p>ULBRECHT M ET AL.: "Assoziation of beta 2-adrenoreceptor variants with bronchial hyperresponsiveness"</p> <p>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,</p> <p>vol. 161, no. 2, February 2000 (2000-02), pages 469-474, XP002188594</p> <p>* page 470, left-hand column, paragraph 5 - right-hand column, paragraph 2 *</p>	1	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	<p>WO 99 06046 A (KOS PHARMA INC)</p> <p>11 February 1999 (1999-02-11)</p> <p>* abstract *</p> <p>* claims 1,3 *</p>	2	

EPO FORM 1303 03.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 6983

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-07-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0008157 A	17-02-2000	AU 5340699 A	28-02-2000
		EP 1141282 A2	10-10-2001
		WO 0008157 A2	17-02-2000
WO 9906046 A	11-02-1999	US 2001006644 A1	05-07-2001
		AU 8680098 A	22-02-1999
		EP 1003515 A1	31-05-2000
		NO 20000407 A	16-03-2000
		WO 9906046 A1	11-02-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ ~~BLURRED~~ OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox